Adequan for Horses - i.m. for Horses 1-Vial (5 mL) - [Inflammation Relief]

If you're seeking a comprehensive solution that not only alleviates the symptoms of your horse's joint problems but also addresses the underlying degenerative disease process, Adequan i.m. Single Dose could be an excellent choice.

Dual-Action Relief for Equine Joint Issues:

1. Symptom Relief (Anti-Inflammatory Effects):

Adequan i.m. provides significant anti-inflammatory effects, offering relief from the common symptoms of joint damage in horses, including heat, swelling, pain, and lameness. Following an intramuscular injection, Adequan reaches full therapeutic levels in the synovial fluid within just two hours, providing fast-acting comfort.

2. Disease Modification (Blocking Degenerative Enzymes & Stimulating Repair):

Beyond symptom relief, Adequan possesses a potent ability to block the action of destructive enzymes that contribute to ongoing joint inflammation, cartilage breakdown, and the thinning of synovial fluid. Furthermore, Adequan stimulates the synovial membrane to produce new, viscous synovial fluid, replacing the inadequate fluid produced after injury. This improved synovial fluid helps the joint regain its crucial ability to lubricate and protect itself against further inflammation while also supporting cartilage nutrition.

Additionally, Adequan actively attaches itself to damaged cartilage, where it positively influences cartilage metabolism. This action supports the cartilage repair process, aiming to regenerate and maintain healthy joint structure.

The Unique Advantage of Adequan:

Adequan i.m. stands out as the only joint treatment with proven results in not just reducing the inflammation and pain associated with degenerative joint disease in horses, but also in actively helping to slow or stop the degenerative process. It simultaneously stimulates the production of new, healthy joint fluid and essential cartilage components. With Adequan, you're moving beyond simply treating the symptoms; you're taking proactive steps to address the root of the problem and support long-term joint health.

Indications:

Adequan i.m. is specifically recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and the associated lameness affecting the carpal (knee) and hock joints in horses.

Key Benefits:

• Proven Results: The only joint treatment with scientifically proven efficacy in addressing both symptoms and the degenerative process.
• Fast-Acting: Provides relief within hours of a single intramuscular injection.
• Easy to Use: Convenient single-dose administration.
• Addresses Underlying Disease: Helps to block destructive enzymes and stimulate joint repair.
• Supports Joint Health: Promotes the production of new, lubricating synovial fluid.

Active Ingredient

The active ingredient in Adequan i.m. is Polysulfated Glycosaminoglycan (PSGAG). PSGAG is a complex molecule that plays a vital role in supporting joint health by inhibiting destructive enzymes, stimulating the production of new synovial fluid, and positively affecting cartilage metabolism. The concentration of PSGAG may vary depending on the specific Adequan i.m. product (e.g., single dose, multi-dose).

Dosage and Administration: Adequan i.m. for Horses

The recommended dosage of Adequan i.m. in horses is 500 mg administered intramuscularly every 4 days for a total of 7 treatments over 28 days.

Prior to each injection, ensure the injection site is thoroughly cleansed. Do not mix Adequan i.m. with any other drugs or solvents.

Contraindications:

Currently, there are no known contraindications for the intramuscular use of Polysulfated Glycosaminoglycan (PSGAG), the active ingredient in Adequan i.m.

Warnings:

• Do not administer to horses intended for human consumption.
• Keep out of reach of children.

Precautions:

The safety of Adequan i.m. has not been formally evaluated in horses used for breeding, during pregnancy, or in lactating mares. Exercise caution in these populations.

Animal Safety Studies:

Toxicity studies in horses have shown a wide margin of safety. Doses up to 2,500 mg (5 times the recommended dose) administered intramuscularly twice weekly for 12 weeks did not result in significant clinical or laboratory evidence of toxicity, nor did it cause soreness or swelling at the injection site or in the affected joint.

Storage Instructions:

Store Adequan i.m. at a controlled room temperature between 20°C and 25°C (68°F and 77°F), with permissible short-term temperature variations between 15°C and 30°C (59°F and 86°F). Keep out of reach of children and animals. Discard any unused portion appropriately, and dispose of used needles according to all applicable environmental regulations.

View Adequan i.m. Package Insert (PDF)